|Bid||1,410.60 x 0|
|Ask||1,411.20 x 0|
|Day's range||1,393.30 - 1,462.00|
|52-week range||1,371.00 - 2,746.59|
|Beta (5Y monthly)||0.18|
|PE ratio (TTM)||12.33|
|Earnings date||02 Nov 2022|
|Forward dividend & yield||0.86 (5.95%)|
|Ex-dividend date||18 Aug 2022|
|1y target est||N/A|
Yahoo Finance health care reporter Anjalee Khemlani looks at which pharmaceutical stocks are being affected by litigation surrounding alleged carcinogenic materials in Zantac derivatives.
The legal battle will be rough. Damages, if awarded, could be as high as $45bn, according to Morgan Stanley. Shares in GSK, Haleon and Sanofi began to recover on Friday after the companies said their legal positions were strong.
The FTSE 100 pharmaceutical giant's share price suffered its biggest drop since 1998 on Thursday.